EGFR-targeted Therapy for Gastric Cancer
Phase 2
Recruiting
- Conditions
- Adenocarcinoma of the Stomach
- Interventions
- Drug: Anti-EGFR antibody in combination with weekly paclitaxel
- Registration Number
- NCT04077255
- Lead Sponsor
- National Cancer Center, Korea
- Brief Summary
Based on targeted NGS panel results, metastatic gastric cancer patients with gene amplifications will receive either anti-EGFR antibody (GC-1118) in combination with weekly paclitaxel as a second-line therapy.
- Detailed Description
Participants will receive each treatment if the gastric cancer tissue sample reveals either EGFR gene amplification or strong (3+ or 2+) EGFR immunostaining
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 19
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description anti-EGFR Anti-EGFR antibody in combination with weekly paclitaxel Participants will receive GC-1118 in combination with weekly paclitaxel.
- Primary Outcome Measures
Name Time Method Response rate Response rate will be assessed at 8 weeks. Response rate will be assessed using CT/MRI according to RECIST v1.1.
- Secondary Outcome Measures
Name Time Method Progression-free survival From date of enrollment until the date of first documented progression or the date of death from any cause, whichever came first, will be assessed up to 1 year. Time from date of enrollment until the date of first documented progression or the date of death from any cause, whichever came first, will be assessed.
Trial Locations
- Locations (1)
National Cancer Center
🇰🇷Goyang, Gyeonggi, Korea, Republic of